Al-Ola A Abdallah, MD

As director of plasma cell disorders care at The University of Kansas Health System and chair of the US Myeloma Innovations of Research Collaborative (USMIRC), Dr. Al-Ola Abdallah is primarily focused on managing and treating patients with various plasma cell disorders, including myeloma, AL amyloidosis, POEMS, solitary plasmacytoma, MGUS and smoldering myeloma. Additionally, he runs many clinical trials regarding PCD and has developed a multidisciplinary amyloidosis program that involves nephro-oncology, cardio-oncology, neurology and palliative care.

His interest in myeloma began when he joined the Myeloma Institute for Research and Therapy (MIRT) at the University of Arkansas for Medical Sciences as an assistant professor of medicine. Working as a clinician and research subinvestigator in multiple tasks of the treatment protocol, Dr. Abdallah gained a solid foundation of knowledge in chemotherapy administration, mechanism of action, HPC collection and infusion, engraftment, treatment of complications and toxicities, and management of expected side effects.

His experience at MIRT went beyond the clinical aspect. It allowed him the opportunity to witness and participate in each of his patient’s journey with cancer, which was a humbling experience. He was honored to care for them through the difficult and rewarding challenges that come with a cancer diagnosis.

Overall, Dr. Abdallah’s passion for treating myeloma and plasma cell disorders stems from his desire to help patients navigate the complexities of these diseases and provide them with the best possible care. Through his work at the health system, the University of Kansas Medical Center and USMIRC, he strives to collaborate with community oncologists to develop best practices and ultimately improve outcomes for patients.

Academic Profile

https://www.kucancercenter.org/find-a-researcher/researcher-finder-results/alola-abdallah-md